Nivolumab Yields 12-Month Survival of Nearly 60% in Advanced HCC
Interim data from CheckMate 040 showed that nivolumab produces durable responses with promising long-term survival rates in patients with advanced, unresectable hepatocellular carcinoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Ian Ingram Tags: Gastrointestinal Cancer Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Gallbladder Cancer | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology